A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression

Cancer Res. 2007 Apr 1;67(7):3337-44. doi: 10.1158/0008-5472.CAN-06-2480.

Abstract

Overexpression of erbB2 is associated with resistance to apoptosis. We explored whether high level of erbB2 expression by cancer cells allows their targeting using an erbB2-binding peptide (LTVSPWY) attached to the proapoptotic alpha-tocopheryl succinate (alpha-TOS). Treating erbB2-low or erbB2-high cells with alpha-TOS induced similar levels of apoptosis, whereas alpha-TOS-LTVSPWY induced greater levels of apoptosis in erbB2-high cells. alpha-TOS rapidly accumulated in erbB2-high cells exposed to alpha-TOS-LTVSPWY. The extent of apoptosis induced in erbB2-high cells by alpha-TOS-LTVSPWY was suppressed by erbB2 RNA interference as well as by inhibition of either endocytotic or lysosomal function. alpha-TOS-LTVSPWY reduced erbB2-high breast carcinomas in FVB/N c-neu transgenic mice. We conclude that a conjugate of a peptide targeting alpha-TOS to erbB2-overexpressing cancer cells induces rapid apoptosis and efficiently suppresses erbB2-positive breast tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / metabolism*
  • Cell Line, Tumor
  • Humans
  • Oligopeptides / administration & dosage
  • Oligopeptides / pharmacokinetics*
  • Protein Binding
  • Receptor, ErbB-2 / biosynthesis*
  • Receptor, ErbB-2 / metabolism
  • Tocopherols
  • Vitamin E / administration & dosage
  • Vitamin E / analogs & derivatives*
  • Vitamin E / pharmacokinetics

Substances

  • Oligopeptides
  • Vitamin E
  • Receptor, ErbB-2
  • Tocopherols